Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study

Coad Thomas Dow,1,2 Calvin B Harley3 1McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI, USA; 2Chippewa Valley Eye Clinic, Eau Claire, Wisconsin, WI, USA; 3Independent Telomere Biology Consultant, Murphys, CA, USA Purpose: Telomere attrition and corresponding cellular...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dow CT, Harley CB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Age-Related Macular Degeneration Telomerase Telomere Telomerase Activation RPE Senescence Micro-perimetry MAIA Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6965b67848784f74a658b8fcb26fda3a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6965b67848784f74a658b8fcb26fda3a
record_format	dspace
spelling	oai:doaj.org-article:6965b67848784f74a658b8fcb26fda3a2021-12-02T01:30:11ZEvaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study1177-5483https://doaj.org/article/6965b67848784f74a658b8fcb26fda3a2016-01-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-an-oral-telomerase-activator-for-early-age-related-macul-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Coad Thomas Dow,1,2 Calvin B Harley3 1McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI, USA; 2Chippewa Valley Eye Clinic, Eau Claire, Wisconsin, WI, USA; 3Independent Telomere Biology Consultant, Murphys, CA, USA Purpose: Telomere attrition and corresponding cellular senescence of the retinal pigment epithelium contribute to the changes of age-related macular degeneration. Activation of the enzyme telomerase can add telomeric DNA to retinal pigment epithelium chromosomal ends and has been proposed as a treatment for age-related macular degeneration. We report the use of a small molecule, oral telomerase activator (TA)-65 in early macular degeneration. This study, focusing on early macular degeneration, provides a model for the use of TAs in age-related disease.Method: Thirty-eight (38) patients were randomly assigned to a 1-year, double-blinded, placebo-controlled interventional study with arms for oral TA-65 or placebo. Macular functions via micro-perimetry were the primary measured outcomes.Results: The macular function in the arm receiving the TA-65 showed significant improvement relative to the placebo control. The improvement was manifest at 6 months and was maintained at 1 year: macular threshold sensitivity (measured as average dB [logarithmic decibel scale of light attenuation]) improved 0.97 dB compared to placebo (P-value 0.02) and percent reduced thresholds lessened 8.2% compared to the placebo arm (P-value 0.04). Conclusion: The oral TA significantly improved the macular function of treatment subjects compared to controls. Although this study was a pilot and a larger study is being planned, it is noteworthy in that it is, to our knowledge, the first randomized placebo-controlled study of a TA supplement. Keywords: drusen, macular degeneration, micro-perimetry, senescence, telomerase activation, telomereDow CTHarley CBDove Medical PressarticleAge-Related Macular Degeneration Telomerase Telomere Telomerase Activation RPE Senescence Micro-perimetry MAIAOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 243-249 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Age-Related Macular Degeneration Telomerase Telomere Telomerase Activation RPE Senescence Micro-perimetry MAIA Ophthalmology RE1-994
spellingShingle	Age-Related Macular Degeneration Telomerase Telomere Telomerase Activation RPE Senescence Micro-perimetry MAIA Ophthalmology RE1-994 Dow CT Harley CB Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
description	Coad Thomas Dow,1,2 Calvin B Harley3 1McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, WI, USA; 2Chippewa Valley Eye Clinic, Eau Claire, Wisconsin, WI, USA; 3Independent Telomere Biology Consultant, Murphys, CA, USA Purpose: Telomere attrition and corresponding cellular senescence of the retinal pigment epithelium contribute to the changes of age-related macular degeneration. Activation of the enzyme telomerase can add telomeric DNA to retinal pigment epithelium chromosomal ends and has been proposed as a treatment for age-related macular degeneration. We report the use of a small molecule, oral telomerase activator (TA)-65 in early macular degeneration. This study, focusing on early macular degeneration, provides a model for the use of TAs in age-related disease.Method: Thirty-eight (38) patients were randomly assigned to a 1-year, double-blinded, placebo-controlled interventional study with arms for oral TA-65 or placebo. Macular functions via micro-perimetry were the primary measured outcomes.Results: The macular function in the arm receiving the TA-65 showed significant improvement relative to the placebo control. The improvement was manifest at 6 months and was maintained at 1 year: macular threshold sensitivity (measured as average dB [logarithmic decibel scale of light attenuation]) improved 0.97 dB compared to placebo (P-value 0.02) and percent reduced thresholds lessened 8.2% compared to the placebo arm (P-value 0.04). Conclusion: The oral TA significantly improved the macular function of treatment subjects compared to controls. Although this study was a pilot and a larger study is being planned, it is noteworthy in that it is, to our knowledge, the first randomized placebo-controlled study of a TA supplement. Keywords: drusen, macular degeneration, micro-perimetry, senescence, telomerase activation, telomere
format	article
author	Dow CT Harley CB
author_facet	Dow CT Harley CB
author_sort	Dow CT
title	Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
title_short	Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
title_full	Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
title_fullStr	Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
title_full_unstemmed	Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
title_sort	evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/6965b67848784f74a658b8fcb26fda3a
work_keys_str_mv	AT dowct evaluationofanoraltelomeraseactivatorforearlyagerelatedmaculardegenerationapilotstudy AT harleycb evaluationofanoraltelomeraseactivatorforearlyagerelatedmaculardegenerationapilotstudy
_version_	1718403020574687232

Evaluation of an oral telomerase activator for early age-related macular degeneration - a pilot study

Ejemplares similares